Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Pharmacology of Combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease


Affiliations
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India
     

   Subscribe/Renew Journal


This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is as used in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.

Keywords

Mesalazine, Rifaximin, Inflammatory Bowel Disease, Pharmacology.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 171

PDF Views: 2




  • Pharmacology of Combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease

Abstract Views: 171  |  PDF Views: 2

Authors

V. Prajapati Krishna
Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India
C. Jain Vinit
Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India
Prajapati Neelam
Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, India

Abstract


This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is as used in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.

Keywords


Mesalazine, Rifaximin, Inflammatory Bowel Disease, Pharmacology.